Abstract
Gemcitabine plus cisplatin (GC) is currently the standard regimen for advanced biliary tract cancers (BTC), but its effectiveness remains to be improved. PD-1 blockade and chemotherapy have demonstrated important therapeutic advantages in BTC (TOP-AZ). Further, the addition of PD-1 to anlotinib has improved the clinical results in the second-line therapy for additional carcinomas, including cervical cancer and HCC, for which therapeutic options have been limited. The effectiveness and safety of sintilimab plus anlotinib in treating metastatic or recurrent GBC are being evaluated in this study.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
